Peptide LibraryResearch statistics
Larazotide research: publications and trials
At a glance
Publications, all years
45
Since 2007
Publications in 2026 so far
1
Through November 1, 2026
Human clinical research
15.9%
7 of 44 classified
Registered clinical trials
10
ClinicalTrials.gov
Randomized controlled trials
5
Publications reporting an RCT in people
Systematic reviews and meta-analyses
1
Preclinical studies
52.3%
17 animal · 5 in vitro · 1 computational
Records that only mention it
38
Not counted above
Status in the library: In clinical trials. 1 publications are not yet classified by study type.
What to keep in mind
- Some completed trials have neither posted results nor a linked results publication.
Publications by year
Larazotide publications by year and evidence
Show the data
| Year | Human clinical research | Preclinical (animal, in vitro, computational) | Reviews and meta-analyses | Other and not yet classified | Total |
|---|---|---|---|---|---|
| 2007 | 1 | 0 | 0 | 0 | 1 |
| 2008 | 0 | 1 | 1 | 0 | 2 |
| 2011 | 0 | 2 | 1 | 0 | 3 |
| 2012 | 2 | 2 | 0 | 0 | 4 |
| 2013 | 0 | 1 | 0 | 2 | 3 |
| 2015 | 1 | 0 | 1 | 0 | 2 |
| 2016 | 0 | 0 | 1 | 1 | 2 |
| 2017 | 0 | 1 | 0 | 0 | 1 |
| 2019 | 0 | 0 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 0 | 1 | 2 |
| 2021 | 1 | 5 | 4 | 1 | 11 |
| 2022 | 1 | 3 | 0 | 0 | 4 |
| 2023 | 0 | 0 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 0 | 0 | 1 |
| 2025 | 1 | 5 | 0 | 0 | 6 |
| 2026 (to date) | 0 | 1 | 0 | 0 | 1 |
Study types
| Animal study | 17 |
|---|---|
| Review | 9 |
| In vitro study | 5 |
| Randomized controlled trial | 5 |
| Editorial, letter or other | 4 |
| Other clinical trial | 1 |
| Computational study | 1 |
| Meta-analysis | 1 |
| Observational human study | 1 |
| Not yet classified | 1 |
Research areas
From MeSH major topics. A paper can be in several areas.
| Gastrointestinal | 34 |
|---|---|
| Metabolic health | 17 |
| Immune system | 15 |
| Antimicrobial and infectious disease | 5 |
| Tissue repair | 4 |
| Dermatology | 1 |
| Endocrinology | 1 |
| Musculoskeletal | 1 |
| Neurological and mental health | 1 |
Registered clinical trials
3 of 7 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.
Completed: 8 · Terminated: 2
Phase 1: 2 · Phase 2: 7 · Phase 3: 1
Human trials and evidence reviews
Meta-analyses, systematic reviews and trials in people, newest first.
- Larazotide acetate for treatment of celiac disease: A systematic review and meta-analysis of randomized controlled trials.
Clinics and research in hepatology and gastroenterology · July 31, 2021 · Meta-analysis · cited 53 times · open access
PMID 34339872 · DOI 10.1016/j.clinre.2021.101782 · Reviews and meta-analyses
- Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide.
Science translational medicine · July 30, 2025 · Randomized controlled trial · cited 2 times
PMID 40737433 · DOI 10.1126/scitranslmed.adu4284 · Human clinical research
- Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial.
Gastroenterology · February 13, 2015 · Randomized controlled trial · cited 264 times · open access
PMID 25683116 · DOI 10.1053/j.gastro.2015.02.008 · Human clinical research
- Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study.
Alimentary pharmacology & therapeutics · November 19, 2012 · Randomized controlled trial · cited 202 times
PMID 23163616 · DOI 10.1111/apt.12147 · Human clinical research
- A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge.
The American journal of gastroenterology · July 24, 2012 · Randomized controlled trial · cited 187 times · open access
PMID 22825365 · DOI 10.1038/ajg.2012.211 · Human clinical research
- The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study.
Alimentary pharmacology & therapeutics · September 1, 2007 · Randomized controlled trial · cited 280 times · open access
PMID 17697209 · DOI 10.1111/j.1365-2036.2007.03413.x · Human clinical research
- Zonulin Antagonist, Larazotide (AT1001), As an Adjuvant Treatment for Multisystem Inflammatory Syndrome in Children: A Case Series.
Critical care explorations · February 18, 2022 · Other clinical trial · cited 29 times · open access
PMID 35211683 · DOI 10.1097/cce.0000000000000641 · Human clinical research
Most cited
By OpenAlex citation count. Citations measure attention, not quality or correctness.
- Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis.
Nature communications · April 24, 2020 · Animal study · cited 497 times · open access
PMID 32332732 · DOI 10.1038/s41467-020-15831-7 · Animal studies
- Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse.
Gut · October 1, 2008 · Animal study · cited 323 times · open access
PMID 18829978 · DOI 10.1136/gut.2008.150888 · Animal studies
- The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study.
Alimentary pharmacology & therapeutics · September 1, 2007 · Randomized controlled trial · cited 280 times · open access
PMID 17697209 · DOI 10.1111/j.1365-2036.2007.03413.x · Human clinical research
- Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial.
Gastroenterology · February 13, 2015 · Randomized controlled trial · cited 264 times · open access
PMID 25683116 · DOI 10.1053/j.gastro.2015.02.008 · Human clinical research
- Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier.
The Journal of clinical investigation · July 1, 2021 · Observational human study · cited 243 times · open access
PMID 34032635 · DOI 10.1172/jci149633 · Human clinical research
Latest publications
- Potassium-Competitive Acid Blocker Increases Ileal Permeability and Exacerbates Ileal Inflammation under Stress Conditions in a Mouse Model of Eosinophilic Enteritis.
Digestion · April 20, 2026 · Animal study · cited 0 times
PMID 42008374 · DOI 10.1159/000552062 · Animal studies
- Larazotide Acetate Protects the Intestinal Mucosal Barrier from Anoxia/Reoxygenation Injury via Various Cellular Mechanisms.
Biomedicines · October 12, 2025 · In vitro study · cited 3 times · open access
PMID 41153766 · DOI 10.3390/biomedicines13102483 · In vitro studies
- Antibacterial hyaluronic acid hydrogel with sustained release of larazotide as effective colitis treatment.
Journal of controlled release : official journal of the Controlled Release Society · September 5, 2025 · Animal study · cited 7 times
PMID 40915363 · DOI 10.1016/j.jconrel.2025.114205 · Animal studies
- Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide.
Science translational medicine · July 30, 2025 · Randomized controlled trial · cited 2 times
PMID 40737433 · DOI 10.1126/scitranslmed.adu4284 · Human clinical research
- Characterizing <i>zonulin</i> and <i>par2</i> Expression in Zonulin Transgenic and Zonulin Inhibition Mouse Models of Motility and Inflammation.
International journal of molecular sciences · July 2, 2025 · Animal study · cited 0 times · open access
PMID 40650159 · DOI 10.3390/ijms26136381 · Animal studies
- Preventive effects of Larazotide acetate (AT-1001) on non-alcoholic fatty liver diseases (NAFLD) in a mouse model.
Pediatrics and neonatology · June 20, 2025 · Animal study · cited 1 times · open access
PMID 40562584 · DOI 10.1016/j.pedneo.2025.01.016 · Animal studies
- The PAR2 Antagonist Larazotide Can Mitigate Acute Histamine-Stimulated Epithelial Barrier Disruption in Keratinocytes: A Potential Adjunct Treatment for Atopic Dermatitis.
JID innovations : skin science from molecules to population health · April 3, 2025 · In vitro study · cited 1 times · open access
PMID 40330848 · DOI 10.1016/j.xjidi.2025.100369 · In vitro studies
- Ameliorative Effects of Larazotide Acetate on Intestinal Permeability and Bacterial Translocation in Acute Pancreatitis Model in Rats.
Digestive diseases and sciences · March 5, 2024 · Animal study · cited 3 times · open access
PMID 38441784 · DOI 10.1007/s10620-024-08326-8 · Animal studies
- Zonulin as a Potential Therapeutic Target in Microbiota-Gut-Brain Axis Disorders: Encouraging Results and Emerging Questions.
International journal of molecular sciences · April 19, 2023 · Review · cited 86 times · open access
PMID 37108711 · DOI 10.3390/ijms24087548 · Reviews and meta-analyses
- Rational design of the zonulin inhibitor AT1001 derivatives as potential anti SARS-CoV-2.
European journal of medicinal chemistry · October 19, 2022 · In vitro study · cited 18 times · open access
PMID 36332548 · DOI 10.1016/j.ejmech.2022.114857 · In vitro studies
How this is counted
PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology
Search terms: AT-1001 (with larazotide or zonulin or celiac or coeliac or tight junction); INN-202; Larazotida; Larazotide
(((TITLE_ABS:"AT-1001" OR TITLE_ABS:"AT1001") AND (TITLE_ABS:"larazotide" OR TITLE_ABS:"zonulin" OR TITLE_ABS:"celiac" OR TITLE_ABS:"coeliac" OR TITLE_ABS:"tight junction")) OR (TITLE_ABS:"INN-202" OR CHEM:"INN-202" OR TITLE_ABS:"INN202" OR CHEM:"INN202") OR (TITLE_ABS:"Larazotida" OR CHEM:"Larazotida") OR (TITLE_ABS:"Larazotide" OR CHEM:"Larazotide")) AND SRC:MED
Cite this page
Peptide Library. (2026, November 2). Larazotide research statistics (Version weekly-2026-11-01) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/larazotide